Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics May 13 | 2026Makary Resigns; Novo OASIS 4 Data; Altimmune Q1 ’26 Earnings; Lilly SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN Full Data; Insulet Initiates O6 vs. O5 StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics May 12 | 2026STEP UP Wegovy HD Data; New Novo Obesity + T1DM Study; Fractyl Q1 ’26 Earnings and CTA Authorization of RJVA-001; Roche 2026 Diagnostics DayPurchase Blast
$599
Posted in: Other, Topics May 11 | 2026Cytokinetics Shares Aficamten Data; FDA Launches Pilot One-Day Inspectional AssessmentsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics May 08 | 2026Arrowhead, Structure, Senseonics, and Tandem Q1 ’26 Earnings; New Pfizer Obesity Combination StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics May 07 | 2026Sanofi to Pull Tzield Application from CNPV Program; Zealand Q1 ’26 Earnings; GSK Targets ALK7; Lilly Expands US Manufacturing Investment; Roche Acquires PathAIPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Insulin Delivery, Other, Topics May 06 | 2026Madrigal and Insulet Q1 ’26 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, Topics May 06 | 2026Wegovy Pill Shines As Novo Raises FY 2026 guidance; Q1 ’26 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics May 05 | 2026Pfizer and Vertex Q1 ’26 Earnings; Madrigal Partners for siRNA MASH Asset; Novo Evaluates New Dose of Cagrisema; Cytokinetics Shares Topline ACACIA-HCM ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics May 04 | 2026Sirius Posts New Obesity Study; Amgen Expands US Manufacturing Investment; Insulet Initiates T2DM FCL StudyPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other, Topics May 01 | 2026Amgen and Dexcom Q1 ’26 Earnings; Zealand to Elect Camilla Sylvest to Board; Esperion Gets Acquired; Senseonics Announces $80M Public Offering; Ozempic Pill Launches in USPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 30 | 2026Lilly, Viking, and Merck Q1 ’26 Earnings; FDA Semaglutide and Tirzepatide Compounding ExclusionsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Apr 29 | 2026AZ, AbbVie, Regeneron, Ionis, and GSK Q1 ’26 Earnings; Zealand and Roche to Advance Petrelintide to Ph3Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 28 | 2026Topline SYNCHRONIZE-1 Data; Rocket Sells PRV; Novartis Q1 ’26 Earnings; Biomea COVALENT-112 DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Apr 27 | 2026Ascletis Completes Ph2 Enrollment for ASC30 in T2DM; GSK’s Efimosfermin Breakthrough Therapy and PRIME Designations; Tandem Control-IQ+ Pregnancy Indication; Tandem Mobi Correction; Sagimet Business Updates and Stock PricingPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Apr 24 | 2026Additional Foundayo Prescription Trends; Regeneron MFN Deal; Arrowhead Positive CHMP Opinion; Eversense 365 CGM Launches in EUPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 23 | 2026Roche and Sanofi Q1 ’26 Earnings; Topline Ph3 PIONEER TEENS Data; Hims & Hers Expands Integration to LillyDirect; Amgen Management ChangesPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, Topics Apr 22 | 2026CMS Delays Launch of Obesity BALANCE Model; Sanofi’s Tzield Receives Black Box Warning Following Pediatric Label Expansion; Beta Bionics Q1 ’26 Earnings; Pfizer’s Ecnoglutide Injection Available for Pre-Order in ChinaPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Apr 21 | 2026Pfizer’s Andrew Baum to Depart at the End of 2026; Amazon Launches AOM Management Program; Dexcom Opens First OUS CGM Manufacturing Site; Kailera Closes IPO; BioAge Reports Additional Ph1 NLRP3i Data; Abbott Wins Preliminary Injunction Appeal Against SinocarePurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other, Topics Apr 20 | 2026New Foundayo DTC Ad; Roche Shares New INN for CT-388; April CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Apr 17 | 2026Early Foundayo Prescription Trends; Kailera Announces IPO Pricing; AZ’s Partner Initiates Ph1 FIH Study of Monthly Dual Agonist; ViCentra Eliminates Waiting Period for Kailedo Patch Pump in Select EU CountriesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
